bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.10.10.681722

Bacterial exposure drives immune ageing

Abstract

The immune system is uniquely capable of both regenerating and ageing the rest of the organism based on its own state1. Understanding the driving forces behind alterations in the immune system with age2 has thus potential to lead to interventions against ageing in general3. However, the factors driving immune ageing remain largely unknown4. Here we show that alterations in response to bacterial exposure are a key driving force of immune ageing. Studying a longitudinal cohort with their immune system characterised in high-dimension2, we devised a phenotype-driven gene co-regulation analysis through which we unravel the immune-ageing role for genes regulated by miRNAs previously reported to cause gut leakiness5. Hypothesizing increased bacterial exposure as a driver of immune ageing, we estimated the exposure of each individuals immune system to bacteria through analysing the residual bacterial DNA content in their immune cells6. We found that the total bacterial load is unrelated to the subjects chronological or immune age, but predicts the magnitude of change in immune age over the next year. Finally, we rationalise previously observed alterations in cellular composition of the immune system associated with ageing2 by finding that the immune cell subtypes most increasing in their frequency are highly enriched in expressing bacterial response genes. Our results thus earmark bacterial exposure as the candidate driver to be counteracted in anti-ageing interventions and the immune cell residual bacterial DNA content as a biomarker for the immune systems most at risk of ageing. Overall, these results offer a new paradigm for investigating gut health in the context of immune ageing7,8.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Feldman, E., Hruzik, M., Lukacisin, M., Shen-Orr, S. S.. 2025-10-13. Bacterial exposure drives immune ageing. https://doi.org/10.1101/2025.10.10.681722

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗